title: Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids.
abstract: BACKGROUND
  CYP3A5 and MDR1 polymorphisms have been shown to influence tacrolimus blood concentrations and dose requirements. The aim is to determine whether these polymorphisms also affect sirolimus trough concentrations and dose requirements after kidney transplantation.
  
  
  METHODS
  Eighty-five renal transplant recipients receiving sirolimus were included. Twenty-four were treated with a combined sirolimus-tacrolimus regimen. Eighty-one patients received steroids. Sirolimus and tacrolimus were adjusted to a target therapeutic window. CYP3A5 (intron 3) and MDR1 (exons 12, 21, 26) genotypes were correlated to the adjusted trough concentrations and dose requirements for both sirolimus and tacrolimus.
  
  
  RESULTS
  There were no significant correlation between adjusted sirolimus trough concentrations or dose requirements and genetic polymorphisms. In a multiple regression model, adjusted-prednisone dose was involved with a positive or negative effect when considering sirolimus dose requirements or adjusted concentrations, respectively. In the subgroup of patients treated by tacrolimus and sirolimus, adjusted tacrolimus doses were higher in patients carrying at least one CYP3A5 *1 allele (median 0.083 vs. 0.035 mg/kg for CYP3A5*3/*3 patients, P<0.05). Adjusted-prednisolone dose and CYP3A5 polymorphism explained up to 61% of the variability in tacrolimus dose requirements.
  
  
  CONCLUSIONS
  Unlike tacrolimus, sirolimus adjusted trough concentrations and dose requirements seem not affected by CYP3A5 and MDR1 polymorphisms. Adjusted-prednisone dose has a significant impact on tacrolimus and sirolimus dose requirements.
authors.affiliation: Kidney and Pancreas Transplantation Unit, Université Catholique de Louvain, Saint Luc University Hospital, Brussels, Belgium. Michel.Mourad@chir.ucl.ac.be
authors.forename: Michel
authors.initials: M
authors.lastname: Mourad
authors.forename: Georges
authors.initials: G
authors.lastname: Mourad
authors.forename: Pierre
authors.initials: P
authors.lastname: Wallemacq
authors.forename: Valérie
authors.initials: V
authors.lastname: Garrigue
authors.forename: Christophe
authors.initials: C
authors.lastname: Van Bellingen
authors.forename: Valérie
authors.initials: V
authors.lastname: Van Kerckhove
authors.forename: Martine
authors.initials: M
authors.lastname: De Meyer
authors.forename: Jacques
authors.initials: J
authors.lastname: Malaise
authors.forename: Djamila Chaib
authors.initials: DC
authors.lastname: Eddour
authors.forename: Dominique
authors.initials: D
authors.lastname: Lison
authors.forename: Jean Paul
authors.initials: JP
authors.lastname: Squifflet
authors.forename: Vincent
authors.initials: V
authors.lastname: Haufroid
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics*; D000328:Adult; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005838:Genotype; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000097:blood; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D011241:Prednisone / Q000008:administration & dosage; D020123:Sirolimus / Q000008:administration & dosage* / Q000097:blood; D013256:Steroids / Q000008:administration & dosage; D016559:Tacrolimus / Q000008:administration & dosage* / Q000097:blood
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D007166:Immunosuppressive Agents; D013256:Steroids; D003577:Cytochrome P-450 Enzyme System; C104464:CYP3A protein, human; C510164:CYP3A5 protein, human; D051544:Cytochrome P-450 CYP3A; D011241:Prednisone; D020123:Sirolimus; D016559:Tacrolimus